Overview

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

...
More »
Stock Quote
NASDAQ - CDXC
Price$3.83
Change (%) Stock is Up 0.17 (4.64%)
Volume187,122
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
05/14/18ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board
World-Renowned British Chemist to Assist in Uncovering New Applications for Nicotinamide Riboside and Mitochondrial Health IRVINE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Professor Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of  Cambridge, England, to the Scientific Advisor... 
Printer Friendly Version
05/10/18ChromaDex Corporation Reports First Quarter 2018 Financial Results
- First Quarter 2018 Net Revenues Increased by 95% to $6.6 Million - IRVINE, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today first quarter 2018 financial results. First Quarter 2018 Highlights vs. First Quarter 2017 Net sales up 95%, fueled by growth of TRU NIAGEN®; Gross profit as a percentage of net sales flat at approximately 48%, which include... 
Printer Friendly Version
05/03/18ChromaDex Sets First Quarter 2018 Financial Results on Thursday, May 10, 2018
IRVINE, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, will report financial results for the first quarter of 2018 on Thurs., May 10, 2018. The Company’s financial results for the period will be reported via press release after the close of regular stock market trading hours. The press release will be followed by a conference call at 4:30 p.m. ET / 1:30 p.m. PT with the Comp... 
Printer Friendly Version
What's New
Download DocumentationMarch 2018 Investor Presentation
Download DocumentationQ1 2018 Earnings Presentation
Download Documentation2018 Q1 Quarterly Report on Form 10Q
Download Documentation2018 Proxy Statement
Download Documentation2017 Annual Report on Form 10K
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.